Anagram Therapeutics: Funding, Investors & Team (Sep 2026)
Anagram Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, orally delivered enzyme therapeutics. These therapies aim to treat serious diseases caused by malabsorption syndromes and nutrient deficiencies. The company is dedicated to advancing enzyme replacement therapies that are currently entering clinicaltrials, particularly for conditions such as cystic fibrosis. Anagram Therapeutics leverages its expertise in biotechnology to create innovative solutions for unmet medical needs.
Anagram Therapeutics has raised $250M across 1 funding round on record, the most recent an undisclosed round of $250M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Anagram Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Anagram Therapeutics Funding Rounds
Anagram Therapeutics Founders and Leadership Team
Contact details for the Anagram Therapeutics team: 1 of 1 has an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Anagram Therapeutics Funding Compared to Other Biotechnology Startups
Anagram Therapeutics' latest round of $250M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Anagram Therapeutics in Biotechnology and Boston
Companies Similar to Anagram Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Anagram Therapeutics Funding FAQs
What does Anagram Therapeutics do?
Anagram Therapeutics is a clinical stage biopharmaceutical company focused on developing novel, orally delivered enzyme therapeutics. These therapies aim to treat serious diseases caused by malabsorption syndromes and nutrient deficiencies. The company is dedicated to advancing enzyme replacement therapies that are currently entering clinicaltrials, particularly for conditions such as cystic fibrosis. Anagram Therapeutics leverages its expertise in biotechnology to create innovative solutions for unmet medical needs.
How much funding has Anagram Therapeutics raised?
Anagram Therapeutics has raised $250M across 1 round on record. The most recent is an undisclosed round of $250M announced in May 2026.
When did Anagram Therapeutics last raise funding?
Anagram Therapeutics' most recent funding round on record is an undisclosed round of $250M, announced in May 2026.
Who founded Anagram Therapeutics?
FundedIQ lists Robert Gallotto (Founder) at Anagram Therapeutics.
Where is Anagram Therapeutics headquartered?
Anagram Therapeutics is based in Boston, Massachusetts, United States.
How many employees does Anagram Therapeutics have?
Anagram Therapeutics is in the 11-50 employee band.
How does Anagram Therapeutics' funding compare to other Biotechnology startups?
Anagram Therapeutics' latest round of $250M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Anagram Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Anagram Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.